Valeant in talks with Carl Zeiss to sell eye surgery assets

|By:, SA News Editor

According to people close to the matter, Valeant Pharmaceuticals (NYSE:VRX) is currently negotiating with Germany's Carl Zeiss Meditec to sell its Bausch + Lomb unit's surgical products business, which could fetch $2B.

Selling assets is one way Valeant is paying down debt.

Last November, Allergan and TPG were rumored to be suitors for the business but nothing happened.

Valeant is off a fraction premarket.

Subscribe for full text news in your inbox